Dae Hyun Yoo Selected Research

CT-P13

1/2021	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
1/2021	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
1/2021	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
6/2020	A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
6/2017	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
2/2017	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
2/2017	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
1/2017	CT-P13 in the treatment of rheumatoid arthritis.
4/2016	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
1/2016	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dae Hyun Yoo Research Topics

Disease

25	Rheumatoid Arthritis 01/2022 - 10/2013
6	Ankylosing Spondylitis 06/2020 - 10/2013
4	Tuberculosis (Tuberculoses) 03/2021 - 07/2013
2	Adult-Onset Still's Disease 02/2021 - 02/2002
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2017 - 01/2016
2	Systemic Scleroderma (Systemic Sclerosis) 09/2017 - 04/2006
2	Necrosis 03/2017 - 07/2013
1	Herpes Zoster 01/2022
1	Pleurisy (Pleuritis) 02/2021
1	Pneumonia (Pneumonitis) 02/2021
1	Leukocytosis (Pleocytosis) 02/2021
1	Hyperferritinemia 02/2021
1	Infections 01/2021
1	Myositis (Idiopathic Inflammatory Myopathies) 09/2020
1	Joint Diseases (Joint Disease) 11/2019
1	Lupus Nephritis 05/2018
1	Proteinuria 05/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Pleural Effusion (Pleural Effusions) 09/2017
1	Diabetes Mellitus 09/2017
1	Disease Progression 01/2017
1	Arthritis (Polyarthritis) 01/2017
1	Macrophage Activation Syndrome 01/2017
1	Osteoarthritis 12/2014
1	Pain (Aches) 12/2014
1	Autoimmune Diseases (Autoimmune Disease) 07/2013
1	Colonic Neoplasms (Colon Cancer) 07/2003
1	Inflammation (Inflammations) 07/2003
1	Insulin Resistance 07/2003
1	Cardiomyopathies (Cardiomyopathy) 02/2002
1	Polymyositis 02/2002
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 02/2002
1	Muscle Weakness 02/2002
1	Chronic Hepatitis B 02/2002
1	Hepatitis B 02/2002

Drug/Important Bio-Agent (IBA)

16	Biosimilar PharmaceuticalsIBA 01/2021 - 10/2013
13	CT-P13IBA 01/2021 - 10/2013
12	Infliximab (Remicade)FDA Link 01/2021 - 10/2013
8	Rituximab (Mabthera)FDA Link 12/2020 - 01/2017
7	CT-P10IBA 12/2020 - 01/2017
3	Pharmaceutical PreparationsIBA 06/2020 - 02/2002
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 07/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2017 - 11/2015
2	Biological ProductsIBA 01/2017 - 08/2014
2	AntibodiesIBA 03/2015 - 10/2013
1	Janus Kinase InhibitorsIBA 01/2022
1	Interleukin-18 (Interleukin 18)IBA 02/2021
1	InterleukinsIBA 02/2021
1	Etanercept (Enbrel)FDA Link 01/2021
1	Adalimumab (Humira)FDA Link 01/2021
1	Monoclonal AntibodiesIBA 09/2020
1	baricitinibIBA 01/2020
1	Interleukin-1 (Interleukin 1)IBA 11/2019
1	Interleukin-6 InhibitorsIBA 11/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2018
1	CreatinineIBA 05/2018
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 05/2018
1	Carbon MonoxideIBA 09/2017
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 09/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2016
1	HLA-DR beta-ChainsIBA 01/2016
1	Peptides (Polypeptides)IBA 03/2015
1	EtoricoxibIBA 12/2014
1	Celecoxib (Celebrex)FDA Link 12/2014
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2014
1	Antirheumatic Agents (DMARD)IBA 08/2014
1	Methotrexate (Mexate)FDA LinkGeneric 10/2013
1	Interferon-gamma (Interferon, gamma)IBA 07/2013
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2006
1	PPAR-gamma AgonistsIBA 07/2003
1	PPAR gammaIBA 07/2003
1	Immunoglobulins (Immunoglobulin)IBA 02/2002
1	SteroidsIBA 02/2002
1	InterferonsIBA 02/2002
1	Intravenous Immunoglobulins (IVIG)FDA Link 02/2002
1	Interferon-alpha (Interferon Alfa)IBA 02/2002

Therapy/Procedure

2	Therapeutics 03/2021 - 05/2018
1	Biological Therapy 08/2017